CeGaT, a Leading German Diagnostics Laboratory, selects N-of-One to Provide Clinical Interpretation for Next-Generation Sequencing Tests

  • Posted by 3mediaweb
  • On May 28, 2014
  • 0 Comments
LEXINGTON, Mass., May 28, 2014 – N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with CeGaT, a leading, innovative laboratory in Germany that provides a wide array of molecular diagnostics tests. Under this agreement, N-of-One will provide clinical interpretation for CeGaT’s next-generation sequencing (NGS) tests done for […]
Read More

N-of-One Announces Agreement with Mayo Clinic to Provide Clinical Interpretation Support for Molecular Diagnostics Program

  • Posted by 3mediaweb
  • On May 21, 2014
  • 0 Comments
LEXINGTON, Mass., May 21, 2014 – N-of-One, the leading provider of clinical interpretation for precision medicine in oncology, today announced an agreement with Mayo Clinic to provide access to clinical interpretation information to aid in highly complex molecular diagnostics. Under the terms of the agreement, in select cases, N-of-One solutions will assist in the identification […]
Read More

N-of-One Selected by Guardant Health to Provide Clinical Interpretation for Guardant360™ Tests

  • Posted by 3mediaweb
  • On May 19, 2014
  • 0 Comments
LEXINGTON, Mass., May 19, 2014 – N-of-One, the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with Guardant Health to provide clinical decision support for Guardant360™, a breakthrough blood test that enables next generation sequencing of solid tumor DNA. Financial terms of the agreement are not disclosed. Guardant360 is the […]
Read More

N-of-One Selected by OncoDNA, a Leading European Diagnostic Laboratory, to Provide Clinical Interpretation for Next-Generation Sequencing Tests Worldwide

  • Posted by 3mediaweb
  • On May 15, 2014
  • 0 Comments
– Largest Belgium Lab to Use N-Of-One Clinical Interpretation for All NGS and Other Molecular Testing – LEXINGTON, Mass., May 15, 2014 – N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with OncoDNA, the first company in Europe to provide personalized medicine in oncology based on the […]
Read More
BACK TO
TOP
LEARN
MORE